Business - Briefly   

FDA approval for Aurobindo Pharma drug

HYDERABAD: Aurobindo Pharma has received the first tentative new drug application (NDA) approval from the U.S. Food and Drug Administration for fixed dose combination drug product containing Lamivudine, Zidovudine and Nevirapine tablets used in the treatment of HIV-1 infection. The three drugs are now available in a single tablet, according to a company release.

Printer friendly page  
Send this article to Friends by E-Mail

Stories in this Section

Honda launches the Civic model
Cognizant to focus on media space
Hotels in Northeast to get 'industry' status
LIC launches unit linked pension plan
UTI Mutual Fund's micro-pension initiative
LIC collects Rs.101 crores through sale of ULIPs
Canara Bank hikes interest on NRE, FCNR deposits
`Make natural vanillin mandatory in ice-creams'
Rupee recovers
Early gains not held on BSE
Exchange rates
Bullion rates
Godrej Consumer eyes South African brand
GM India sales up 53 p.c. in June
Hero Honda registers 23 p.c. growth in June
TMB raises NRE, FCNR-B deposit rates
Polaris Retail solution for Delhi store
Wyeth launches vaccine for infants
CPCL gets new Director (Technical)
New Chief Executive for DBS Cholamandalam
Govt. extends ban on export of pulses
TDSAT rejects petition
Tulip gets LoI for NLD, ILD licence
IAASB Chairman reappointed
Dr. Reddy's launches Alfoo
FDA approval for Aurobindo Pharma drug
Reliance, Intel announce tie-up
MOIL signs MoU with Samancor
Satyam services for Project Hope in China
Zen Technologies wins ISMS
Electro Investment hikes stake in BPL to 43 p.c.
Enzen Global sets up second facility
Indian edition of PC World from IDG Media
BEL gets new Director (Other Units)
Karnataka Bank hikes FCNR (B) rates
GoAir offers discount to Govt. staff, senior citizens
Air Sahara announces low economy class fare

Copyright © 2006, The Hindu. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu